MCID: MLG064
MIFTS: 40

Malignant Ependymoma

Categories: Cancer diseases, Genetic diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Malignant Ependymoma

MalaCards integrated aliases for Malignant Ependymoma:

Name: Malignant Ependymoma 12 15
Ependymal Tumors 12 55
Experimental Organism Malignant Ependymoma 73
Anaplastic Ependymoma 73
Ependymoma of Brain 73
Ependymal Neoplasm 12
Ependymal Tumor 73

Classifications:



External Ids:

Disease Ontology 12 DOID:5074
NCIt 50 C6770

Summaries for Malignant Ependymoma

Disease Ontology : 12 A malignant glioma that is derived from ependymal cells, a type of glial cell, located in ventricle lining within the central part of the brain.

MalaCards based summary : Malignant Ependymoma, also known as ependymal tumors, is related to benign ependymoma and spinal cord ependymoma, and has symptoms including seizures, vomiting and headache. An important gene associated with Malignant Ependymoma is NF2 (Neurofibromin 2), and among its related pathways/superpathways is DNA damage_ATM/ATR regulation of G1/S checkpoint. The drugs Vincristine and Cyclophosphamide have been mentioned in the context of this disorder. Affiliated tissues include brain, lung and bone, and related phenotypes are Increased proliferation and immune system

Related Diseases for Malignant Ependymoma

Diseases in the Ependymoma family:

Benign Ependymoma Malignant Ependymoma
Malignant Adult Ependymoma

Diseases related to Malignant Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 74)
# Related Disease Score Top Affiliating Genes
1 benign ependymoma 32.0 GFAP NF2
2 spinal cord ependymoma 32.0 EPB41 NF2
3 ependymoma 30.8 GFAP NF2 RELA
4 ependymoblastoma 30.0 GFAP TP53
5 anaplastic ependymoma 29.9 GFAP NF2 RELA
6 subependymal glioma 11.1
7 brain ependymoma 11.1
8 intraventricular meningioma 10.2 GFAP NF2
9 rhabdoid meningioma 10.2 GFAP NF2
10 plexiform schwannoma 10.2 GFAP NF2
11 cornea cancer 10.2 GFAP NF2
12 atypical neurofibroma 10.2 GFAP NF2
13 trigeminal nerve neoplasm 10.2 GFAP NF2
14 neurilemmoma of the fifth cranial nerve 10.2 GFAP NF2
15 neurilemmoma 10.2 GFAP NF2
16 tanycytic ependymoma 10.2 GFAP NF2
17 cerebellopontine angle tumor 10.2 GFAP NF2
18 neuroma 10.1 GFAP NF2
19 olfactory groove meningioma 10.1 NF2 TP53
20 frontal convexity meningioma 10.1 GFAP TP53
21 gliofibroma 10.1 GFAP TP53
22 protoplasmic astrocytoma 10.1 GFAP TP53
23 meninges sarcoma 10.1 GFAP TP53
24 central nervous system primitive neuroectodermal neoplasm 10.1 GFAP TP53
25 cerebral neuroblastoma 10.1 GFAP TP53
26 mixed glioma 10.1 GFAP TP53
27 cerebral ventricle cancer 10.1 GFAP TP53
28 anterior cranial fossa meningioma 10.1 NF2 TP53
29 glioma susceptibility 1 10.1 GFAP TP53
30 fibrillary astrocytoma 10.1 GFAP TP53
31 benign glioma 10.1 GFAP TP53
32 pleomorphic xanthoastrocytoma 10.1 GFAP TP53
33 small cell sarcoma 10.1 NF2 TP53
34 meningioma, radiation-induced 10.1 GFAP NF2
35 spinal cord astrocytoma 10.1 GFAP TP53
36 gliomatosis cerebri 10.1 GFAP TP53
37 papilloma of choroid plexus 10.1 GFAP TP53
38 choroid plexus cancer 10.1 GFAP TP53
39 necrotizing sialometaplasia 10.1 GFAP TP53
40 optic nerve neoplasm 10.1 NF2 TP53
41 cystic teratoma 10.1 GFAP TP53
42 central nervous system benign neoplasm 10.1 GFAP TP53
43 cerebellar liponeurocytoma 10.1 GFAP TP53
44 pineal gland cancer 10.1 GFAP PTPRS
45 medullomyoblastoma 10.1 GFAP TP53
46 juvenile pilocytic astrocytoma 10.1 GFAP TP53
47 adult medulloblastoma 10.1 GFAP TP53
48 cellular schwannoma 10.1 NF2 TP53
49 brain glioma 10.1 GFAP TP53
50 optic nerve glioma 10.0 GFAP TP53

Graphical network of the top 20 diseases related to Malignant Ependymoma:



Diseases related to Malignant Ependymoma

Symptoms & Phenotypes for Malignant Ependymoma

UMLS symptoms related to Malignant Ependymoma:


seizures, vomiting, headache, nausea

GenomeRNAi Phenotypes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased proliferation GR00094-A 8.62 NF2 TP53

MGI Mouse Phenotypes related to Malignant Ependymoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.91 CD207 EPB41 ERCC5 GFAP NF2 RELA
2 digestive/alimentary MP:0005381 9.88 ERCC5 GFAP LOXL3 PTPRS RELA TP53
3 integument MP:0010771 9.8 ERCC5 LOXL3 NF2 PTPRS RELA TP53
4 mortality/aging MP:0010768 9.76 EPB41 ERCC5 GFAP LOXL3 NF2 PTPRS
5 liver/biliary system MP:0005370 9.73 CD207 EPB41 ERCC5 NF2 RELA TP53
6 respiratory system MP:0005388 9.43 CD207 LOXL3 NF2 PTPRS RELA TP53
7 vision/eye MP:0005391 9.17 ARVCF GFAP LOXL3 NF2 PTPRS RELA

Drugs & Therapeutics for Malignant Ependymoma

Drugs for Malignant Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 205)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
2
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
3
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 38904 498142
4
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
5
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
6
Donepezil Approved Phase 3,Phase 2 120014-06-4 3152
7
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
8
Dopamine Approved Phase 3,Early Phase 1,Not Applicable 51-61-6, 62-31-7 681
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
11 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
12 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1
13 Keratolytic Agents Phase 3,Phase 1,Phase 2
14 Alkylating Agents Phase 3,Phase 2,Phase 1
15 Antineoplastic Agents, Phytogenic Phase 3,Phase 1,Phase 2
16 Podophyllotoxin Phase 3,Phase 1,Phase 2 518-28-5
17 Immunologic Factors Phase 3,Phase 2,Phase 1
18 Antirheumatic Agents Phase 3,Phase 2
19 Antimitotic Agents Phase 3,Phase 1,Phase 2
20 Etoposide phosphate Phase 3,Phase 2
21 Topoisomerase Inhibitors Phase 3,Phase 2
22 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
23 Dermatologic Agents Phase 3,Phase 1,Phase 2
24 Cola Phase 3,Phase 1
25 Adjuvants, Anesthesia Phase 3
26 Liver Extracts Phase 3,Phase 2,Phase 1
27 Anesthetics, Intravenous Phase 3
28 Analgesics, Opioid Phase 3
29 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
30 Anesthetics, General Phase 3
31 Analgesics Phase 3,Phase 2,Phase 1
32 Narcotics Phase 3
33 Anesthetics Phase 3
34 Neurotransmitter Agents Phase 3,Phase 2,Early Phase 1,Not Applicable
35 Nootropic Agents Phase 3,Phase 2
36 Cholinergic Agents Phase 3,Phase 2
37 Cholinesterase Inhibitors Phase 3,Phase 2
38 Central Nervous System Stimulants Phase 3,Phase 2
39 Dopamine Agents Phase 3,Early Phase 1,Not Applicable
40 Dexmethylphenidate Hydrochloride Phase 3
41 Neurotransmitter Uptake Inhibitors Phase 3
42 Dopamine Uptake Inhibitors Phase 3
43
Mesna Approved, Investigational Phase 2 3375-50-6 598
44
Lenograstim Approved, Investigational Phase 2,Phase 1 135968-09-1
45
Carmustine Approved, Investigational Phase 1, Phase 2,Phase 2 154-93-8 2578
46
Ethanol Approved Phase 1, Phase 2 64-17-5 702
47
Dacarbazine Approved, Investigational Phase 2,Phase 1 4342-03-4 5351166
48
Temozolomide Approved, Investigational Phase 2,Phase 1 85622-93-1 5394
49
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
50
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 88)
# Name Status NCT ID Phase Drugs
1 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
2 Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
3 Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma Recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
4 Methylphenidate to Improve Quality of Life in Patients Undergoing Radiation Therapy for Brain Tumors Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
5 Phase I/II Trial of Safety and Anti-tumor Efficacy of AXL1717(Picropodophyllin) in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
6 Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma Unknown status NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
7 Carmustine Followed By Surgery in Treating Patients With Recurrent Supratentorial Malignant Glioma or Metastatic Brain Neoplasm Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
8 Everolimus for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
9 Etoposide Plus Cisplatin in Treating Patients With Recurrent Ependymomas Completed NCT00002876 Phase 2 cisplatin;etoposide
10 Combination Chemotherapy Plus Radiation Therapy in Treating Adult Patients With Brain Cancer Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
11 Poly-ICLC in Treating Patients With Recurrent or Progressive Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
12 Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer Completed NCT00492089 Phase 2 bevacizumab;placebo
13 Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
14 Veliparib and Temozolomide in Treating Patients With Recurrent Glioblastoma Completed NCT01026493 Phase 1, Phase 2 temozolomide 60 mg x 21 days;temozolomide 75 mg x 21 days;ABT-888 20 mg x 21 days;ABT-888 40 mg x 21 days;Temozolomide 150 mg x 5 days;ABT-888 40 mg x 5 days
15 Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors Completed NCT01032200 Phase 2 Armodafinil
16 Levetiracetam or Pregabalin in Treating Seizures in Patients Undergoing Chemotherapy and/or Radiation Therapy For Primary Brain Tumors Completed NCT00629889 Phase 2 levetiracetam;pregabalin
17 Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
18 Temozolomide in Treating Patients With Recurrent Glioblastoma Multiforme or Other Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
19 Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) With Bevacizumab and Irinotecan for Malignant Glioma Completed NCT00352521 Phase 2 bevacizumab;irinotecan
20 Magnetic Resonance Imaging and Magnetic Resonance Spectroscopic Imaging in Evaluating Patients Who Are Undergoing Treatment for Gliomas Completed NCT00274755 Phase 2 chemotherapy
21 Combination Chemotherapy Followed by Radiation Therapy in Treating Patients With Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Ependymoma Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
22 Chemotherapy and Vaccine Therapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation and Interleukin-2 in Treating Patients With Recurrent or Refractory Brain Cancer Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
23 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary Brain Tumors Completed NCT00003478 Phase 1, Phase 2
24 Phase II Studies Of Donepezil And Ginkgo Biloba In Irradiated Brain Tumor Completed NCT00070161 Phase 2 donepezil hydrochloride
25 Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Primary or Metastatic Brain Cancers Completed NCT00002752 Phase 1, Phase 2
26 Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
27 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
28 Carboplatin and Bevacizumab for Recurrent Ependymoma Recruiting NCT01295944 Phase 2 Carboplatin;Bevacizumab
29 Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas Active, not recruiting NCT01478321 Phase 2 Temozolomide
30 Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer Active, not recruiting NCT00445965 Phase 2
31 Marizomib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial, and Spinal Cord Ependymoma Not yet recruiting NCT03727841 Phase 2 Marizomib
32 Antineoplaston Therapy in Treating Patients With Ependymoma Terminated NCT00003479 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
33 Ritonavir and Lopinavir in Treating Patients With Progressive or Recurrent High-Grade Glioma Terminated NCT01095094 Phase 2 ritonavir;lopinavir
34 Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors Terminated NCT01836549 Phase 2 imetelstat sodium
35 Photodynamic Therapy in the Treatment of Malignant Intracranial Tumors Withdrawn NCT00243490 Phase 2
36 Functional Magnetic Resonance Imaging and 1H-Nuclear Magnetic Resonance Spectroscopic Imaging in Treating Patients With Newly Diagnosed Brain Tumors Withdrawn NCT00005083 Phase 2
37 Enzastaurin and Temozolomide in Treating Patients With Primary Gliomas Unknown status NCT00516607 Phase 1 enzastaurin hydrochloride;temozolomide
38 Lonafarnib and Temozolomide in Treating Patients With Recurrent Primary Supratentorial Gliomas Unknown status NCT00083096 Phase 1 lonafarnib;temozolomide
39 Photodynamic Therapy With Porfimer Sodium in Treating Patients With Refractory Brain Tumors Unknown status NCT00002647 Phase 1 verteporfin
40 Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2 Completed NCT01082926 Phase 1
41 Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases Completed NCT01234740 Phase 1 bafetinib
42 Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Completed NCT01131234 Phase 1 Gamma-Secretase Inhibitor RO4929097;Cediranib Maleate
43 Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction Completed NCT00030498 Phase 1 erlotinib hydrochloride
44 RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma Completed NCT01119599 Phase 1 Gamma-Secretase Inhibitor RO4929097;Temozolomide
45 Mibefradil Dihydrochloride and Temozolomide in Treating Patients With Recurrent Glioma Completed NCT01480050 Phase 1 temozolomide;Mibefradil
46 Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma Completed NCT00730613 Phase 1
47 A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors Completed NCT00784914 Phase 1 temsirolimus
48 Carmustine in Treating Patients With Recurrent Malignant Glioma Completed NCT00004028 Phase 1 carmustine
49 Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment Completed NCT00544284 Phase 1 bortezomib;temozolomide
50 Sodium Stibogluconate and IFNa-2b Followed By CDDP, VLB and DTIC Treating Pts.With Advanced Melanoma or Other Cancers Completed NCT00498979 Phase 1 cisplatin;sodium stibogluconate;dacarbazine;vinblastine

Search NIH Clinical Center for Malignant Ependymoma

Genetic Tests for Malignant Ependymoma

Anatomical Context for Malignant Ependymoma

MalaCards organs/tissues related to Malignant Ependymoma:

41
Brain, Lung, Bone, Spinal Cord, Pineal

The Foundational Model of Anatomy Ontology organs/tissues related to Malignant Ependymoma:

19
Ventricle Lining

Publications for Malignant Ependymoma

Articles related to Malignant Ependymoma:

(show all 40)
# Title Authors Year
1
EANO guidelines for the diagnosis and treatment of ependymal tumors. ( 29194500 )
2018
2
Advantages of high b-value diffusion-weighted imaging for preoperative differential diagnosis between embryonal and ependymal tumors at 3 T MRI. ( 29571787 )
2018
3
Prognostic Implications of Histological Clear Cells in High-Grade Intracranial Ependymal Tumors: A Retrospective Analysis from a Tertiary Care Hospital in Pakistan. ( 29682026 )
2018
4
Prognostic factors in ependymal tumors: Molecular biology trumps histopathology. ( 26954808 )
2016
5
Genetic differences on intracranial versus spinal cord ependymal tumors: a meta-analysis of genetic researches. ( 27637901 )
2016
6
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. ( 25965575 )
2015
7
Ventricular and extraventricular ependymal tumors in 18 cats. ( 22798290 )
2013
8
Prognostic relevance of global histone 3 lysine 9 acetylation in ependymal tumors. ( 24116725 )
2013
9
Response to temozolomide in supratentorial multifocal recurrence of malignant ependymoma. ( 21498732 )
2011
10
Cytologic findings in malignant ependymoma: a case report. ( 21053591 )
2010
11
Adult ependymal tumors: prognosis and the M. D. Anderson Cancer Center experience. ( 20511182 )
2010
12
Cachexia secondary to intracranial anaplastic (malignant) ependymoma in a boxer dog. ( 19796316 )
2009
13
A primary malignant ependymoma of the abdominal cavity: a case report and review of the literature. ( 19238432 )
2009
14
Sacrococcygeal immature teratoma with malignant ependymoma component. ( 19492320 )
2009
15
Ependymal tumors. ( 19322537 )
2009
16
Distribution of 4-hydroxynonenal-protein conjugates as a marker of lipid peroxidation and parameter of malignancy in astrocytic and ependymal tumors of the brain. ( 20210242 )
2009
17
Patterns of brain infiltration and secondary structure formation in supratentorial ependymal tumors. ( 18716554 )
2008
18
Expression of cyclo-oxygenase-2 in ependymal tumors. ( 17080719 )
2006
19
Supratentorial malignant ependymoma in childhood: 16 years without relapse after hemispherectomy. ( 15095106 )
2005
20
Ependymal tumors in childhood. ( 15770637 )
2005
21
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia. ( 15912507 )
2005
22
Inverse correlation between genetic aberrations and malignancy grade in ependymal tumors: a paradox? ( 15015776 )
2004
23
A multicenter study of the prognosis and treatment of adult brain ependymal tumors. ( 15022290 )
2004
24
Ependymal tumors. ( 14585232 )
2003
25
Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. ( 11238062 )
2001
26
Indications for a tumor suppressor gene at 22q11 involved in the pathogenesis of ependymal tumors and distinct from hSNF5/INI1. ( 11547953 )
2001
27
Ependymal tumors: A review of their diagnostic surgical pathology. ( 9705595 )
1998
28
Primary malignant ependymoma of the lung. ( 1548954 )
1992
29
Synaptophysin expression in "ependymal tumors" induced by ethyl-nitrosourea in rats. ( 1443043 )
1992
30
Extracranial metastases of malignant ependymoma--case report. ( 1699151 )
1990
31
Immunocytochemical analysis of intermediate filaments in human ependymal tumors. ( 2454716 )
1988
32
Abnormal cilia in a malignant ependymoma. ( 3776464 )
1986
33
Acute leukaemia following malignant ependymoma: a case report. ( 3857395 )
1985
34
Subarachnoid haemorrhage due to widely metastatising malignant ependymoma. ( 4080060 )
1985
35
Differential diagnosis of chordoma, chondroid, and ependymal tumors as aided by anti-intermediate filament antibodies. ( 6192722 )
1983
36
Malignant ependymoma involving the temporal bone with remote metastasis. ( 4429899 )
1974
37
Malignant ependymoma in a cat. ( 4731360 )
1973
38
Malignant ependymoma in a dog. ( 14497569 )
1962
39
Malignant Ependymoma Masquerading as Tuberculous Meningitis: Clinico-Pathological Conference. ( 28907958 )
1962
40
Malignant ependymoma infiltrating the scalp. ( 14810337 )
1951

Variations for Malignant Ependymoma

Expression for Malignant Ependymoma

Search GEO for disease gene expression data for Malignant Ependymoma.

Pathways for Malignant Ependymoma

Pathways related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.27 RELA TP53

GO Terms for Malignant Ependymoma

Biological processes related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleotide-excision repair GO:0006289 9.16 ERCC5 TP53
2 spinal cord development GO:0021510 8.96 LOXL3 PTPRS
3 positive regulation of pri-miRNA transcription by RNA polymerase II GO:1902895 8.62 RELA TP53

Molecular functions related to Malignant Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.65 ARVCF CD207 EPB41 ERCC5 GFAP LOXL3
2 protein N-terminus binding GO:0047485 8.92 EPB41 ERCC5 RELA TP53

Sources for Malignant Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....